Cargando…
A New Variant of Mutational and Polymorphic Signatures in the ERG11 Gene of Fluconazole-Resistant Candida albicans
BACKGROUND: Resistance to antifungal drugs for treating Candida infections remains a major concern globally despite the range of medications available. Most of these drugs target key proteins essential to the life cycle of the organism. An enzyme essential for fungal cell membrane integrity, lanoste...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9213107/ https://www.ncbi.nlm.nih.gov/pubmed/35747333 http://dx.doi.org/10.2147/IDR.S360973 |
_version_ | 1784730763228348416 |
---|---|
author | Odiba, Arome Solomon Durojaye, Olanrewaju Ayodeji Ezeonu, Ifeoma Maureen Mgbeahuruike, Anthony Christian Nwanguma, Bennett Chima |
author_facet | Odiba, Arome Solomon Durojaye, Olanrewaju Ayodeji Ezeonu, Ifeoma Maureen Mgbeahuruike, Anthony Christian Nwanguma, Bennett Chima |
author_sort | Odiba, Arome Solomon |
collection | PubMed |
description | BACKGROUND: Resistance to antifungal drugs for treating Candida infections remains a major concern globally despite the range of medications available. Most of these drugs target key proteins essential to the life cycle of the organism. An enzyme essential for fungal cell membrane integrity, lanosterol 14–α demethylase (CYP51), is encoded by the ERG11 gene in Candida species. This enzyme is the target of azole–based drugs. The organism has, however, devised molecular adaptations to evade the activity of these drugs. MATERIALS AND METHODS: Classical methods were employed to characterize clinical isolates sampled from women and dogs of reproductive age. For fluconazole efficacy studies, CLSI guidelines on drug susceptibility testing were used. To understand the susceptibility pattern, various molecular and structural analytic approaches, including sequencing, in silico site-directed mutagenesis, and protein-ligand profiling, were applied to the ERG11 gene and CYP51 protein sequences. Several platforms, comprising Clustal Omega, Pymol plugin manager, Pymol molecular visualizer, Chimera–curated Dynameomics rotamer library, protein–ligand interaction profiler, Charmm36 force field, GROMACS, Geneious, and Mega7, were employed for this analysis. RESULTS: The following Candida species distribution was obtained: 37.84% C. albicans, 8.12% C. glabrata, 10.81% C. krusei, 5.41% C. tropicalis, and 37.84% of other unidentified Candida species. Two codons in the nucleotide sequence of the wild-type (CTC and CCA) coding for LEU–370 and PRO–375, respectively, were mutated to L370S and P375H in the resistant strain. The mutation stabilized the protein at the expense of the heme moiety. We found that the susceptible isolate from dogs (Can–iso–029/dog) is closely related to the most resistant isolate from humans. CONCLUSION: Taken together, our results showed new mutations in the heme-binding pocket of caCYP51 that explain the resistance to fluconazole exhibited by the Candida isolates. So far, the L370S and P375H resistance-linked mutations have not been previously reported. |
format | Online Article Text |
id | pubmed-9213107 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-92131072022-06-22 A New Variant of Mutational and Polymorphic Signatures in the ERG11 Gene of Fluconazole-Resistant Candida albicans Odiba, Arome Solomon Durojaye, Olanrewaju Ayodeji Ezeonu, Ifeoma Maureen Mgbeahuruike, Anthony Christian Nwanguma, Bennett Chima Infect Drug Resist Original Research BACKGROUND: Resistance to antifungal drugs for treating Candida infections remains a major concern globally despite the range of medications available. Most of these drugs target key proteins essential to the life cycle of the organism. An enzyme essential for fungal cell membrane integrity, lanosterol 14–α demethylase (CYP51), is encoded by the ERG11 gene in Candida species. This enzyme is the target of azole–based drugs. The organism has, however, devised molecular adaptations to evade the activity of these drugs. MATERIALS AND METHODS: Classical methods were employed to characterize clinical isolates sampled from women and dogs of reproductive age. For fluconazole efficacy studies, CLSI guidelines on drug susceptibility testing were used. To understand the susceptibility pattern, various molecular and structural analytic approaches, including sequencing, in silico site-directed mutagenesis, and protein-ligand profiling, were applied to the ERG11 gene and CYP51 protein sequences. Several platforms, comprising Clustal Omega, Pymol plugin manager, Pymol molecular visualizer, Chimera–curated Dynameomics rotamer library, protein–ligand interaction profiler, Charmm36 force field, GROMACS, Geneious, and Mega7, were employed for this analysis. RESULTS: The following Candida species distribution was obtained: 37.84% C. albicans, 8.12% C. glabrata, 10.81% C. krusei, 5.41% C. tropicalis, and 37.84% of other unidentified Candida species. Two codons in the nucleotide sequence of the wild-type (CTC and CCA) coding for LEU–370 and PRO–375, respectively, were mutated to L370S and P375H in the resistant strain. The mutation stabilized the protein at the expense of the heme moiety. We found that the susceptible isolate from dogs (Can–iso–029/dog) is closely related to the most resistant isolate from humans. CONCLUSION: Taken together, our results showed new mutations in the heme-binding pocket of caCYP51 that explain the resistance to fluconazole exhibited by the Candida isolates. So far, the L370S and P375H resistance-linked mutations have not been previously reported. Dove 2022-06-17 /pmc/articles/PMC9213107/ /pubmed/35747333 http://dx.doi.org/10.2147/IDR.S360973 Text en © 2022 Odiba et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Odiba, Arome Solomon Durojaye, Olanrewaju Ayodeji Ezeonu, Ifeoma Maureen Mgbeahuruike, Anthony Christian Nwanguma, Bennett Chima A New Variant of Mutational and Polymorphic Signatures in the ERG11 Gene of Fluconazole-Resistant Candida albicans |
title | A New Variant of Mutational and Polymorphic Signatures in the ERG11 Gene of Fluconazole-Resistant Candida albicans |
title_full | A New Variant of Mutational and Polymorphic Signatures in the ERG11 Gene of Fluconazole-Resistant Candida albicans |
title_fullStr | A New Variant of Mutational and Polymorphic Signatures in the ERG11 Gene of Fluconazole-Resistant Candida albicans |
title_full_unstemmed | A New Variant of Mutational and Polymorphic Signatures in the ERG11 Gene of Fluconazole-Resistant Candida albicans |
title_short | A New Variant of Mutational and Polymorphic Signatures in the ERG11 Gene of Fluconazole-Resistant Candida albicans |
title_sort | new variant of mutational and polymorphic signatures in the erg11 gene of fluconazole-resistant candida albicans |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9213107/ https://www.ncbi.nlm.nih.gov/pubmed/35747333 http://dx.doi.org/10.2147/IDR.S360973 |
work_keys_str_mv | AT odibaaromesolomon anewvariantofmutationalandpolymorphicsignaturesintheerg11geneoffluconazoleresistantcandidaalbicans AT durojayeolanrewajuayodeji anewvariantofmutationalandpolymorphicsignaturesintheerg11geneoffluconazoleresistantcandidaalbicans AT ezeonuifeomamaureen anewvariantofmutationalandpolymorphicsignaturesintheerg11geneoffluconazoleresistantcandidaalbicans AT mgbeahuruikeanthonychristian anewvariantofmutationalandpolymorphicsignaturesintheerg11geneoffluconazoleresistantcandidaalbicans AT nwangumabennettchima anewvariantofmutationalandpolymorphicsignaturesintheerg11geneoffluconazoleresistantcandidaalbicans AT odibaaromesolomon newvariantofmutationalandpolymorphicsignaturesintheerg11geneoffluconazoleresistantcandidaalbicans AT durojayeolanrewajuayodeji newvariantofmutationalandpolymorphicsignaturesintheerg11geneoffluconazoleresistantcandidaalbicans AT ezeonuifeomamaureen newvariantofmutationalandpolymorphicsignaturesintheerg11geneoffluconazoleresistantcandidaalbicans AT mgbeahuruikeanthonychristian newvariantofmutationalandpolymorphicsignaturesintheerg11geneoffluconazoleresistantcandidaalbicans AT nwangumabennettchima newvariantofmutationalandpolymorphicsignaturesintheerg11geneoffluconazoleresistantcandidaalbicans |